LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 106

Search options

  1. Article: Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition.

    Federman, Noah

    NPJ precision oncology

    2022  Volume 6, Issue 1, Page(s) 62

    Abstract: Desmoid tumor (DT) is a rare, soft tissue neoplasm associated with an unpredictable clinical course. Although lacking metastatic potential, DT is often locally aggressive and invasive, causing significant morbidity. Both sporadic DT and familial ... ...

    Abstract Desmoid tumor (DT) is a rare, soft tissue neoplasm associated with an unpredictable clinical course. Although lacking metastatic potential, DT is often locally aggressive and invasive, causing significant morbidity. Both sporadic DT and familial adenomatous polyposis (FAP)-associated DT are linked to constitutive activation of the Wnt signaling pathway with mutations in the β-catenin oncogene CTNNB1 or the tumor suppressor gene APC, respectively. Cross-talk between the Notch and Wnt pathways, as well as activation of the Notch pathway resulting from dysregulation of the Wnt pathway, suggest a possible therapeutic target for DT. Due to the role γ-secretase plays in Notch signaling through cleavage of the Notch intracellular domain (with subsequent translocation to the nucleus to activate gene transcription), γ-secretase inhibitors (GSIs) have emerged as a potential treatment for DT. Two GSIs, nirogacestat (PF-03084014) and AL102 are in later-stage clinical development; nirogacestat is being evaluated in a phase 3, randomized, placebo-controlled trial while AL102 is being evaluated in a phase 2/3, dose-finding (part A) and placebo-controlled (part B) trial. This review summarizes current understanding of the molecular pathogenesis of DT focusing on dysregulation of the Wnt signaling pathway, crosstalk with the Notch pathway, and the potential therapeutic role for GSIs in DT.
    Language English
    Publishing date 2022-09-06
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2397-768X
    ISSN 2397-768X
    DOI 10.1038/s41698-022-00308-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Erratum: 120 Impact of Undergraduate Clinical Research Experience: Highlighting the UCLA Clinical and Translational Science Institute Research Associates Program (CTSI-RAP) - CORRIGENDUM.

    Piring, Amanda / Morrison, Jim / Federman, Noah / Shaker-Irwin, Laurie / Duong-Brett, Sam

    Journal of clinical and translational science

    2024  Volume 8, Issue 1, Page(s) e68

    Abstract: This corrects the article DOI: 10.1017/cts.2024.117.]. ...

    Abstract [This corrects the article DOI: 10.1017/cts.2024.117.].
    Language English
    Publishing date 2024-04-23
    Publishing country England
    Document type Published Erratum
    ISSN 2059-8661
    ISSN (online) 2059-8661
    DOI 10.1017/cts.2024.523
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: From Mendel to Gene Therapy.

    Jeffrey, Samantha L / Brigham, Don A / Chawla, Sant P / Federman, Noah / Hall, Frederick L / Gordon, Erlinda M

    Anticancer research

    2023  Volume 43, Issue 10, Page(s) 4257–4261

    Language English
    Publishing date 2023-04-03
    Publishing country Greece
    Document type Letter
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    DOI 10.21873/anticanres.16620
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma.

    Selim, Omar / Song, Clara / Kumar, Amy / Phelan, Rebecca / Singh, Arun / Federman, Noah

    Frontiers in oncology

    2023  Volume 13, Page(s) 1244035

    Abstract: This review aims to summarize the putative role of histone deacetylases (HDACs) in rhabdomyosarcoma (RMS) and the effects of HDAC inhibitors (HDACi) on RMS by elucidating and highlighting known oncogenic pathways, mechanisms of resistance, and the ... ...

    Abstract This review aims to summarize the putative role of histone deacetylases (HDACs) in rhabdomyosarcoma (RMS) and the effects of HDAC inhibitors (HDACi) on RMS by elucidating and highlighting known oncogenic pathways, mechanisms of resistance, and the synergistic potential of histone deacetylase inhibitors. We searched two databases (PubMed and Google Scholar) for the keywords "Rhabdomyosarcoma, histone deacetylase, histone deacetylase inhibitors." We excluded three publications that did not permit access to the full text to review and those that focus exclusively on pleiomorphic RMS in adults. Forty-seven papers met the inclusion criteria. This review highlights that HDACi induce cytotoxicity, cell-cycle arrest, and oxidative stress in RMS cells. Ultimately, HDACi have been shown to increase apoptosis and the cessation of embryonal and alveolar RMS proliferation
    Language English
    Publishing date 2023-08-18
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2023.1244035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report.

    Zarrabi, Maiah / Hamilton, Camille / French, Samuel W / Federman, Noah / Nowicki, Theodore S

    Frontiers in immunology

    2023  Volume 14, Page(s) 1156746

    Abstract: Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and its corresponding ligand PD-L1 are being increasingly used for a wide variety of cancers, including refractory sarcomas. Autoimmune hepatitis is a known side effect of ICIs, ...

    Abstract Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and its corresponding ligand PD-L1 are being increasingly used for a wide variety of cancers, including refractory sarcomas. Autoimmune hepatitis is a known side effect of ICIs, and is typically managed with broad, non-specific immunosuppression. Here, we report a case of severe autoimmune hepatitis occurring after anti-PD-1 therapy with nivolumab in a patient with osteosarcoma. Following prolonged unsuccessful treatment with intravenous immunoglobulin, steroids, everolimus, tacrolimus, mycophenolate, and anti-thymoglobulin, the patient was eventually treated with the anti-CD25 monoclonal antibody basiliximab. This resulted in prompt, sustained resolution of her hepatitis without significant side effects. Our case demonstrates that basiliximab may be an effective therapy for steroid-refractory severe ICI-associated hepatitis.
    MeSH term(s) Humans ; Female ; Immune Checkpoint Inhibitors/adverse effects ; Basiliximab ; Hepatitis, Autoimmune/diagnosis ; Hepatitis, Autoimmune/drug therapy ; Hepatitis, Autoimmune/etiology ; Nivolumab/adverse effects ; Antibodies, Monoclonal/adverse effects
    Chemical Substances Immune Checkpoint Inhibitors ; Basiliximab (9927MT646M) ; Nivolumab (31YO63LBSN) ; Antibodies, Monoclonal
    Language English
    Publishing date 2023-05-30
    Publishing country Switzerland
    Document type Case Reports ; Research Support, N.I.H., Extramural ; Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1156746
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Effects of hypertension and use of antihypertensive drugs in pregnancy on the risks of childhood cancers in Taiwan.

    Orimoloye, Helen T / Hu, Ya-Hui / Federman, Noah / Ritz, Beate / Arah, Onyebuchi A / Li, Chung-Yi / Lee, Pei-Chen / Heck, Julia E

    Cancer causes & control : CCC

    2024  

    Abstract: Background: Childhood cancers are associated with high mortality and morbidity, and some maternal prescription drug use during pregnancy has been implicated in cancer risk. There are few studies on the effects of hypertension, preeclampsia, and the use ... ...

    Abstract Background: Childhood cancers are associated with high mortality and morbidity, and some maternal prescription drug use during pregnancy has been implicated in cancer risk. There are few studies on the effects of hypertension, preeclampsia, and the use of antihypertensives in pregnancy on children's cancer risks.
    Objective: This population-based cohort study analyzed the relationship between hypertension, preeclampsia, and antihypertensives taken during pregnancy and the risks of childhood cancers in the offspring.
    Methods: Data on all children born in Taiwan between 2004 and 2015 (N = 2,294,292) were obtained from the Maternal and Child Health Database. This registry was linked with the National Health Insurance Database and Cancer Registry to get the records of maternal use of diuretics or other antihypertensives in pregnancy and records of children with cancer diagnosed before 13 years. We used Cox proportional hazard modeling to estimate the influence of maternal health conditions and antihypertensive drug exposure on the risks of developing childhood cancers.
    Results: Offspring of mothers with hypertension (chronic or gestational) had a higher risk of acute lymphocytic lymphoma [hazard ratio (HR) = 1.87, 95% Confidence Interval (CI) 1.32 - 2.65] and non-Hodgkin's lymphoma (HR = 1.96, 95% CI 1.34 - 2.86). We estimated only a weak increased cancer risk in children whose mothers used diuretics (HR = 1.16, 95% CI 0.77 - 1.74) or used antihypertensives other than diuretics (HR = 1.15, 95% CI 0.86 - 1.54) before birth.
    Conclusions: In this cohort study, children whose mothers had chronic and gestational hypertension had an increased risk of developing childhood cancer.
    Language English
    Publishing date 2024-04-01
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1064022-8
    ISSN 1573-7225 ; 0957-5243
    ISSN (online) 1573-7225
    ISSN 0957-5243
    DOI 10.1007/s10552-024-01864-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Orbital indeterminate cell histiocytosis.

    Oh, Angela J / Sears, Connie M / Vadivelan, Akhila A / Gomperts, Brigitte N / Federman, Noah / Said, Jonathan / Roelofs, Kelsey A

    Orbit (Amsterdam, Netherlands)

    2024  , Page(s) 1–5

    Abstract: An 8-year-old female presented to the oculoplastics clinic with 3 months of left upper eyelid fullness and edema. Examination showed a mass in the left anterior superior orbit with erythema. Imaging demonstrated a well-circumscribed superolateral orbital ...

    Abstract An 8-year-old female presented to the oculoplastics clinic with 3 months of left upper eyelid fullness and edema. Examination showed a mass in the left anterior superior orbit with erythema. Imaging demonstrated a well-circumscribed superolateral orbital mass that was T1 hypointense and T2 hypo-to-iso intense with contrast enhancement. An incisional biopsy was performed via an upper lid crease incision. Histopathology showed aggregates of histiocytic cells with fibrosis and infiltration of eosinophils. Immunohistochemistry revealed positive CD68 and CD163 staining and negative langerin staining, confirming the diagnosis of indeterminate cell histiocytosis. There was no systemic involvement or associated dermatologic findings. Repeat exam 3 months later showed no change in the size of the lesion and the patient was referred to hematology-oncology for treatment. On most recent exam, the patient had no new symptoms or side effects following 3 months of oral hydroxyurea (25 mg/kg/day). Repeat orbital imaging showed no progression of the lesion and the patient will be monitored closely. Here, we report a rare case of isolated orbital indeterminate cell histiocytosis in a young child.
    Language English
    Publishing date 2024-02-19
    Publishing country England
    Document type Journal Article
    ZDB-ID 603157-2
    ISSN 1744-5108 ; 0167-6830
    ISSN (online) 1744-5108
    ISSN 0167-6830
    DOI 10.1080/01676830.2024.2317301
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.

    Federman, Noah / McDermott, Ray

    Expert review of clinical pharmacology

    2019  Volume 12, Issue 10, Page(s) 931–939

    Abstract: ... ...

    Abstract Introduction
    MeSH term(s) Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology ; Gene Fusion ; Humans ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/pathology ; Oncogene Proteins, Fusion/genetics ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacology ; Pyrazoles/administration & dosage ; Pyrazoles/adverse effects ; Pyrazoles/pharmacology ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Pyrimidines/pharmacology ; Quality of Life ; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors ; Receptor Protein-Tyrosine Kinases/genetics
    Chemical Substances ARRY-470 ; Antineoplastic Agents ; Oncogene Proteins, Fusion ; Protein Kinase Inhibitors ; Pyrazoles ; Pyrimidines ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1)
    Language English
    Publishing date 2019-09-10
    Publishing country England
    Document type Journal Article ; Review
    ISSN 1751-2441
    ISSN (online) 1751-2441
    DOI 10.1080/17512433.2019.1661775
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Pediatric Rectal Adenocarcinoma With Mismatch Repair Deficiency Responds to Immunotherapy.

    Qureshi, Naveen / Hoffman, Trevor L / Kaneva, Kristiyana / Zomorrodian, Sina / Scapa, Jason V / Hitchins, Megan P / Federman, Noah

    JCO precision oncology

    2023  Volume 7, Page(s) e2200378

    MeSH term(s) Humans ; Child ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/therapy ; Colorectal Neoplasms/pathology ; Brain Neoplasms ; Adenocarcinoma/genetics ; Adenocarcinoma/therapy ; Adenocarcinoma/pathology ; Immunotherapy
    Language English
    Publishing date 2023-04-13
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.22.00378
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Polyendocrine Autoimmunity and Diabetic Ketoacidosis Following Anti-PD-1 and Interferon α.

    Dasgupta, Aditi / Tsay, Eric / Federman, Noah / Lechner, Melissa G / Su, Maureen A

    Pediatrics

    2022  Volume 149, Issue 4

    Abstract: Immune checkpoint inhibitor (ICI) therapies are now first-line therapy for many advanced malignancies in adults, with emerging use in children. With increasing ICI use, prompt recognition and optimal management of ICI-associated immune-related adverse ... ...

    Abstract Immune checkpoint inhibitor (ICI) therapies are now first-line therapy for many advanced malignancies in adults, with emerging use in children. With increasing ICI use, prompt recognition and optimal management of ICI-associated immune-related adverse events (IRAEs) are critical. Nearly 60% of ICI-treated adults develop IRAEs, which commonly manifest as autoimmune skin, gastrointestinal, and endocrine disease and can be life-threatening. The incidence, presentation, and disease course of spontaneous autoimmune diseases differ between adults and children, but the pattern of pediatric IRAEs is currently unclear. We report a case of a pediatric patient presenting with new onset autoimmune diabetes mellitus and diabetic ketoacidosis during ICI treatment of fibrolamellar hepatocellular carcinoma (FLC). Distinct from spontaneous type 1 diabetes mellitus (T1DM), this patient progressed rapidly and was negative for known β cell autoantibodies. Additionally, the patient was positive for 21-hydroxylase autoantibodies, suggesting development of concomitant adrenal autoimmunity. Current guidelines for the management of IRAEs in adults may not be appropriate for the management of pediatric patients, who may have different autoimmune risks in a developmental context.
    MeSH term(s) Adult ; Autoimmune Diseases ; Autoimmunity ; Child ; Diabetes Mellitus ; Diabetic Ketoacidosis/chemically induced ; Diabetic Ketoacidosis/therapy ; Humans ; Interferon-alpha/adverse effects ; Neoplasms ; Nivolumab/adverse effects ; Polyendocrinopathies, Autoimmune
    Chemical Substances Interferon-alpha ; Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2022-03-03
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 207677-9
    ISSN 1098-4275 ; 0031-4005
    ISSN (online) 1098-4275
    ISSN 0031-4005
    DOI 10.1542/peds.2021-053363
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top